Two decades of Hepatitis E in solid organ transplantation: From endemic insight to unresolved therapeutic questions
Behrendt P, Neumann-Haefelin C

Patrick Behrendt has been leading the Junior Research Group for Translational Virology as part of the Institute for Experimental Virology at TWINCORE in Hannover since 2019. From 2011 to 2019, he worked as a physician scientist at the Institute for Experimental Virology at TWINCORE. Since 2022, Patrick Behrendt has been a senior physician and head of the Ultrasound Unit in the Department of Gastroenterology, Hepatology, Infectiology, and Endocrinology at Hannover Medical School, where he has also been working as a physician since 2010. In 2022, he specialized in General Internal Medicine. Patrick Behrendt completed his doctoral thesis from 2008 to 2010 under the supervision of Prof. Heike Kielstein at the Institute of Pathology at Hannover Medical School. From 2003 to 2009, he studied Human Medicine at Hannover Medical School.
Together with the Department of Structural Biology at the University of Lübeck, human, strongly neutralizing antibodies against HEV were identified and characterized for the first time. These showed a protective effect in the mouse model and are currently being further developed for clinical application, including mRNA-based application methods.
Human, potentially neutralizing antibodies against HEV have advanced the development of new detection methods for the virus in patient samples. Serological and functional analyses are used to determine markers for the course and treatment of chronic infections.
Studies in the cell culture model show that only a few disinfectants are effective against HEV, which provides important information on hygiene measures for HEV infections. We are also working together to test vaccines for pigs as HEV reservoirs.
Monoclonal antibodies are transforming modern medicine. At Helmholtz Infection Medicine at MHH, bringing together TWINCORE and CiiM, advanced technologies and AI drive the development of next-generation human antibodies against major infectious diseases.
Behrendt P, Neumann-Haefelin C
Prallet S, Maier N, Li A, Afting C, Huang H, Hu J, Toprak E, Keya D, Colasanti O, León-Janampa N, Marlet J, Beisel C, Mogler C, Puchas P, Behrendt P, Boettler T, Steinmann E, Saha S, Laketa V, Lohmann V, Wittbrodt J, Hermann C, Dill M, Dao Thi V
Hrabal I, Aliabadi E, Weber S, Ssebyatika G, Krey T, Holicki C, Schmid L, Dinkelborg K, Schröder C, Fast C, Behrendt P, Groschup M, Eiden M
Wahid A, Meyer N, Wundes C, Hüffner L, Janshoff S, Frericks N, Friesland M, Dinkelborg K, Aliabadi E, Laue F, Cornberg M, Maasoumy B, Bremer B, Pischke S, Müller T, Wiesch J, Benckert J, Ulrich R, Hardtke S, Dörge P, Vondran F, Lohse A, Manns M, Todt D, Wedemeyer H, Pietschmann T, Steinmann E, Gömer A, Behrendt P
Hrabal I, Aliabadi E, Reiche S, Weber S, Holicki C, Schmid L, Fast C, Schröder C, Gutjahr B, Behrendt P, Groschup M, Eiden M

Research team from Bochum and Hannover shows that the hepatitis E virus also attacks organs other than the liver

Relay team comes in at rank 536

Neutralising antibodies can prevent severe courses